Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Tiffany A. Traina, MD, FASCO, Kevin Kalinsky, MD, MS, FASCO, Mark E. Robson, MD, FASCO, and Rebecca Shatsky, MD discuss data for CDK4-6 inhibitors, PARP inhibitors, and immune checkpoint inhibitors in the management of early-stage hormone receptor-positive, HER-2-negative breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Integrate biomarkers into clinical practice to stratify recurrence risk and tailor multidisciplinary treatment strategies for patients with early-stage HR+/HER2- breast cancer
• Develop individualized treatment plans for patients with early-stage HR+/HER2- breast cancer based on latest clinical trial evidence and guideline recommendations

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca and Merck Sharp & Dohme Corp.

Chair:

Tiffany A. Traina, MD, FASCO

Associate Professor of Medicine
Weill Cornell Medicine
Associate Attending Physician
Vice Chair, Oncology Department of Medicine
Section Head, Triple Negative Breast Cancer Clinical
Research Program
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Aktis Oncology, AstraZeneca, BioNTech SE, Daiichi Sankyo, Exact Sciences, Genentech/Roche, Gilead Sciences, Merck, Pfizer, Stemline Therapeutics, TerSera, Veracyte, Ellipses Pharma; Grant/Research Funding (to institution): AstraZeneca, Astellas Pharma, BioNTech SE, Daiichi Sankyo, Genentech/Roche, Pfizer

Faculty:

Kevin Kalinsky, MD, MS, FASCO

Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Louisa and Rand Glenn Family Chair in Breast Cancer
Research
Director, Glenn Family Breast Center
Director, Division of Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, GA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, bioTheranostics, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Gilead, Merck, Menarini Silicon Biosystems, Mersana, Mersana, Myovant Sciences, Novartis, Pfizer, ProteinQure, Puma Biotechnology, Regor, Relay Therapeutics, Seattle Genetics

Mark E. Robson, MD, FASCO

Chief, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Foundation Medicine; Grant/Research Funding: Astrazeneca, Artios Pharma, Merck

Rebecca Shatsky, MD

Professor of Medicine
Breast Medical Oncology Team Leader
Director of Breast Cancer Clinical Trials
Director of Inflammatory and Triple Negative Breast Cancer Program
University of California, San Diego
San Diego, CA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daichii Sankyo, Gilead, Guardant Health, Lilly, Novarits, Pfizer, TEMPUS

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on genetic and genomic testing to guide breast cancer treatment and improving quality of life and fertility for woman undergoing endocrine therapy, go to https://www.gotoper.com/sabcs25nuances-enduring.

Release Date

January 19, 2026

Expiration Date

January 19, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.